https://mindmedicinelaw.com/briefing/esketamine-vs-ketamine-clinical-and-policy-distinctions-in-u-s-psychiatric-care-20261019-51707The Psychedelic Journalen2026-10-19T15:05:22.233058+00:00Esketamine vs. Ketamine: Clinical and Policy Distinctions in U.S. Psychiatric Careesketamine, ketamine, fda approval, off-label use, psychiatric care, insurance coverage, clinical trials, prescriber liability, remS program, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/dea-considers-ncnpr-s-bid-to-manufacture-psychedelic-substances-20261019-51578The Psychedelic Journalen2026-10-19T15:04:46.526739+00:00DEA Considers NCNPR's Bid to Manufacture Psychedelic Substancesdea registration, ncnpr, controlled substances, psychedelic research, university of mississippi, bulk manufacturing, clinical trials, research supply chain, policy implications, federal registerhttps://mindmedicinelaw.com/briefing/psilocybin-s-antidepressant-durability-new-evidence-from-year-long-follow-up-20261018-51708The Psychedelic Journalen2026-10-19T15:05:04.599325+00:00Psilocybin’s Antidepressant Durability: New Evidence from Year-Long Follow-Uppsilocybin, depression, clinical trial, placebo, long-term efficacy, psychedelic therapy, FDA, maintenance dosing, integration support, mental health policyhttps://mindmedicinelaw.com/briefing/meditation-and-substance-use-alcohol-cannabis-and-psychedelics-in-practice-20261017-51595The Psychedelic Journalen2026-10-19T15:05:41.968978+00:00Meditation and Substance Use: Alcohol, Cannabis, and Psychedelics in Practicemeditation and substance use, polysubstance use, psychedelics, alcohol and meditation, cannabis, harm reduction, well-being outcomes, psychedelic exceptionalism, public health, behavioral interventionshttps://mindmedicinelaw.com/briefing/ketamine-vs-psilocybin-depression-outcomes-and-durability-compared-20261017-51315The Psychedelic Journalen2026-10-18T15:06:21.996676+00:00Ketamine vs Psilocybin: Depression Outcomes and Durability Comparedketamine, psilocybin, treatment-resistant depression, clinical trial comparison, remission durability, cost-effectiveness, psychedelic therapy, payer coverage, trial design, mental health policyhttps://mindmedicinelaw.com/briefing/public-doubt-and-antidepressant-efficacy-implications-for-psychedelic-policy-20261016-51269The Psychedelic Journalen2026-10-18T15:07:12.202550+00:00Public Doubt and Antidepressant Efficacy: Implications for Psychedelic Policyantidepressant skepticism, psychedelic policy, manufactured doubt, critical psychiatry, public trust in science, regulatory implications, serotonin hypothesis, psychiatric treatment debate, science communication, philosophy of sciencehttps://mindmedicinelaw.com/briefing/iv-vs-subcutaneous-esketamine-for-trd-real-world-outcomes-in-brazil-20261016-51316The Psychedelic Journalen2026-10-18T15:06:33.950677+00:00IV vs. Subcutaneous Esketamine for TRD: Real-World Outcomes in Brazilesketamine, treatment-resistant depression, intravenous administration, subcutaneous administration, real-world evidence, brazil, clinical outcomes, adverse events, psychiatric protocolshttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-severe-depression-efficacy-and-safety-in-acute-suici-20261014-51330The Psychedelic Journalen2026-10-18T15:06:46.309350+00:00Ketamine and Esketamine for Severe Depression: Efficacy and Safety in Acute Suicidality (Brazil, 2026 Review)ketamine, esketamine, severe depression, suicidality, clinical safety, rapid-acting antidepressants, treatment-resistant depression, adverse events, policy implications, Brazilhttps://mindmedicinelaw.com/briefing/ethical-and-practical-dimensions-of-patient-safety-in-es-ketamine-therapy-german-20261008-51298The Psychedelic Journalen2026-10-18T15:07:00.074642+00:00Ethical and Practical Dimensions of Patient Safety in (Es)ketamine Therapy: German Clinical Insightsesketamine therapy, patient vulnerability, ethical care, clinical safety, psychedelic therapy, german psychiatric settings, therapeutic presence, post-acute support, informed consent, standards of care